A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age
A legfontosabb adatok
- Ki végzi
- GlaxoSmithKline
- Hol
- DeSoto, Fort Worth, Glendale, Hartsdale, Lenexa, Meridian, Miami, Miami Lakes, San Diego, Spartanburg, Tucson és Valparaiso (Egyesült Államok)Mind a 12 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 3000 fő, tervezett
- Kezdés
- 2026. okt. 1.
- Várható befejezés
- 2027. júl. 9.
- A vizsgálat típusa
- Beavatkozással járó, 4 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- mRNA Seasonal Flu vaccine
- Comparator 1
- Comparator 2
- A regiszteradat frissítve
- 2026. október 9.
Ki vehet részt
- Életkor
- 18 év – 64 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 15 feltétel megnézéseKevesebb
Ki vehet részt
- Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the eDiary, return for follow-up visits, attendance to study contacts, and ability to access and utilize a phone or other electronic communications) independently or with the assistance of a caregiver
- A male or female participant between and including 18 to 64 years of age at the time of study intervention administration
- Participants of childbearing potential may be enrolled, if the participant:; has practiced adequate contraception for at least 30 days prior to study intervention administration, and; has a negative urine pregnancy test within 24 hours prior to study intervention administration, and; has agreed to continue adequate contraception for at least 8 weeks after study intervention administration
Ki nem vehet részt
- History of test confirmed influenza infection within 180 days prior to study intervention administration
- History of hypersensitivity or allergic reaction to any previous influenza vaccine
- History of hypersensitivity or allergic reaction to any previous mRNA vaccine
- History of Guillain-Barré syndrome (GBS) within 6 weeks of receiving any vaccine
- Administration of an influenza vaccine in the period starting 180 days before the study intervention administration or planned administration prior to Visit 2 during the study
- Planned administration/administration of prohibited vaccines within protocol-defined time windows before or after study intervention administration
- Use of any investigational or non-registered product (other than the study intervention during the period beginning 30 days before the dose of study intervention (Day -29 to Day 1), or their planned use during the study period
- Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune modifying treatments at any time up to the end of the study
- Confirmed or suspected immunosuppressive or immunodeficient condition, except for stable human immunodeficiency virus infection meeting protocol-defined stability criteria
- History of myocarditis or pericarditis considered causally associated with the administration of an mRNA vaccine
- Acute or unstable chronic conditions as determined by medical history and clinical examination
- Pregnant or lactating female participant
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 64 év között vagy?
Helyszínek itt: Egyesült Államok
- DeSoto, TexasHospital not named in the registryContact: Haresh Boghara (principal investigator)Résztvevőt keres
- Fort Worth, TexasHospital not named in the registryContact: William Seger (principal investigator)Résztvevőt keres
- Glendale, WisconsinHospital not named in the registryContact: Abram Burgher (principal investigator)Résztvevőt keres
- Hartsdale, New YorkHospital not named in the registryContact: Michael Gerdis (principal investigator)Résztvevőt keres
- Lenexa, KansasHospital not named in the registryContact: Carlos Fierro (principal investigator)Résztvevőt keres
- Meridian, IdahoHospital not named in the registryContact: Mark Turner (principal investigator)Résztvevőt keres
- Miami, FloridaHospital not named in the registryContact: Rafael Ubeda (principal investigator)Résztvevőt keres
- Miami Lakes, FloridaHospital not named in the registryContact: Jose Cardona (principal investigator)Résztvevőt keres
- San Diego, CaliforniaHospital not named in the registryContact: Donald Brandon (principal investigator)Résztvevőt keres
- Spartanburg, South CarolinaHospital not named in the registryContact: Charles Fogarty (principal investigator)Résztvevőt keres
- Tucson, ArizonaHospital not named in the registryContact: Anita Kohli (principal investigator)Résztvevőt keres
- Valparaiso, IndianaHospital not named in the registryContact: Robert Buynak (principal investigator)Résztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
This clinical trial will study an investigational seasonal influenza vaccine in adults 18 to 64 years of age. The vaccine is based on messenger ribonucleic acid, also called mRNA. The main goals of the study are to learn how well the vaccine helps the body make an immune response against influenza and what medical problems participants may have after vaccination. Researchers will also compare immune responses in adults 18 to 64 years of age from this study, with immune responses in adults 65 years of age and older from another study. Participants will receive 1 injection into the upper arm muscle and will be followed for about 6 months.
A vizsgálat 4 csoportja
- mRNA Seasonal Flu Vaccine - Cohort 1A vizsgált kezelés
Participants 18 to 64 years of age will receive a single dose of investigational mRNA Seasonal Flu vaccine on Day 1.
Kezelés: mRNA Seasonal Flu vaccine
- Comparator 1_Cohort 1Már használt kezelés, összehasonlításként
Participants 18 to 64 years of age will receive a single dose of comparator 1 on Day 1.
Kezelés: Comparator 1
- mRNA Seasonal Flu Vaccine - Cohort 2A vizsgált kezelés
Participants 60 to 64 years of age will receive a single dose of investigational mRNA Seasonal Flu vaccine on Day 1.
Kezelés: mRNA Seasonal Flu vaccine
- Comparator 2_Cohort 2Már használt kezelés, összehasonlításként
Participants 60 to 64 years of age will receive a single dose of comparator 2 on Day 1.
Kezelés: Comparator 2
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase 3 Randomized, Observer-Blind, Controlled Study to Evaluate the Immunogenicity, Reactogenicity and Safety of an mRNA-based Seasonal Influenza Vaccine, in Adults 18-64 Years of Age
- Illeszkedési kérdések
- Forrás: NCT07851246: ki vehet részt
- A regiszteradat frissítve
- 2026. október 9.